Lay Summary: Gemcitabine and oxaliplatin combination is promising but needs more study for mesothelioma.
Most patients with malignant mesothelioma are candidates for systemic chemotherapy during the course of their disease, but no standard regimen has been established. Several phase II single-agent and combination chemotherapy studies have been performed over the past two decades. There are tow studies of the gemcitabine/ oxaliplatin combination to my knowledge, a retropsective revieew and two phase II studies, with small numbers of patients. Although the true impact of chemotherapy in mesothelioma remains to be determined, agents with consistent antitumor activity include the platinum agents and the antifolates. Recent data from a large randomized phase III clinical trial established the superiority of cisplatin/pemetrexed compared to cisplatin alone.
Pasi A. Jänne First-Line Chemotherapy for Malignant Pleural Mesothelioma in
Advances in Pathogenesis, Diagnosis, and Translational Therapies , 2006
ed. Harvey I. Pass, Nicholas J. Vogelzang and Michele Carbone
M. S. Boyar, M. Hesdorffer, R. N. Taub Phase II trial of oxaliplatin and gemcitabine in patients with malignant pleural or peritoneal mesotheliomaJournal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 17133